Serum vasopressin response in patients with intradialytic hypotension: a pilot study

What Was Tested

The paper reports a study of Vasopressin, published as a clinical trial.

Arginine vasopressin (AVP), an endogenous hormone with vasopressor properties, may be inadequately secreted during episodes of intradialytic hypotension (IDH).

To evaluate this, the researchers performed a prospective, observational pilot study of 20 chronic hemodialysis patients assessing the baseline AVP level and trend of AVP with ultrafiltration in patients with a diagnosis of IDH compared with patients without IDH.

Who Took Part

According to the abstract, 20 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Ten symptomatic IDH patients and 10 controls were enrolled and matched for age, gender, and dialysis vintage.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Vasopressin study would be practical.

AVP levels were obtained hourly throughout the dialysis session and during hypotensive episodes.

What Was Measured

PubMed files the paper under topics including Blood Pressure, Case-Control Studies, Diastole, Hemodiafiltration, Hypotension, Kidney Failure, Chronic and Neurophysins.

What This Means in Plain Language

The paper is a pilot study of Vasopressin in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Vasopressin compound page, all human trials.